ClinicalTrials.Veeva

Menu

Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients

Seoul National University logo

Seoul National University

Status

Terminated

Conditions

Biomarker With Neurodegeneration Patients

Study type

Observational

Funder types

Other

Identifiers

NCT01564316
H-0505-148-016

Details and patient eligibility

About

Using to method of Proteomics, for aims to conquer intractable disease, try to access variety experiment. Biomarker is necessary to develop new diagnosis method and target of treatment.

Full description

Following Seoul National University Hospital Institutional Review Board approval, obtain serum and platelet with neurodegeneration patients and control group visited the part of neurology, there'll be analysis to differentiate each other diseases use to method Proteomics. Biomarker will be screening via 1D/2D analysis, Mass analysis, database searching- the MASCOT search tool, SWISS-PROT and etc.

Enrollment

22 patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • neurodegeneration patients and control group include dementia patients visited the part of neurology.
  • over the age of 18
  • when participants can understand subject of this study
  • Total point of Mini Mental state exam(MMSE)should be Under 26 include MCI (mild cognitive impairment) and over GDS score 3points.

Exclusion criteria

  • under eighteen years of age
  • when participants cannot understand subject of this study
  • cannot accept this study

Trial design

22 participants in 1 patient group

neurodegeneration patients
Description:
•neurodegeneration patients and control group include dementia patients visited the part of neurology

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems